Treatment of focal idiopathic hyperhidrosis with Botulinum Toxin Type A clinical predictive factors of relapse-free survival.

Treatment of focal idiopathic hyperhidrosis with Botulinum Toxin Type A: clinical predictive factors of relapse-free survival.

Campanati A, Sandroni L, Gesuita R, Giuliano A, Giuliodori K, Marconi B, Ganzetti G, Offidani A.

Dermatological Clinic, Department of Biostatistics and Medical Information Technology, Polytechnic Marche University, Ancona, Italy External Faculty Member, Professor of Scientific English, Polytechnic Marche University, Ancona, Italy Institute of Epidemiology, Department of Biostatistics and Medical Information Technology, Polytechnic Marche University, Ancona, Italy.

Abstract

Background  No material about the identification of predictive clinical factors of therapeutic response to Botulinum Toxin Type A (BTX-A) in focal idiopathic hyperhidrosis has been found. Objective  To evaluate if age, sex, extension rate of hyperhidrotic area, localization, disease-related impairment of life quality, number of previous local, non-invasive treatments different from BTX-A, and duration of disease, may affect the relapse-free survival (RFS) after a BTX-A treatment in palmar and axillary focal idiopathic hyperhidrosis. Methods  Forty-one patients suffering from palmar hyperhidrosis, and 38 patients suffering from axillary hyperhidrosis received intradermal injections of BTX-A. All patients were clinically screened before and after treatment; they were followed for 15 months after it, according to Hyperhidrosis Disease Severity Scale (HDSS), Minor's test, and DLQI test, to state disease severity, and disease-related impairment of quality of life. Results  The duration of therapeutic effect of BTX-A is not significantly influenced by age (P = 0.783), sex (P = 0.762), extension of hyperhidrotic area (P = 0.770), site of involvement (P = 0.402), disease-induced impairment of life quality (P = 0.745), number of previous therapies (P = 0.730), or site of involvement (P = 0.402). In palmar idiopathic hyperhidrosis, patients with a longer disease history show a shorter duration of RFS after a treatment with BTX-A (P = 0.01). Conclusions  Patients suffering from palmar hyperhidrosis have a longer lasting disease, and a length of disease more than 20 years in these patients influences the RFS after BTX-A treatment.

© 2010 The Authors. Journal of the European Academy of Dermatology and Venereology © 2010 European Academy of Dermatology and Venereology.

PMID: 21054569 [PubMed - as supplied by publisher]